Producer: Cypin Production
Source: eSummit: Market Access, Pricing and Reimbursement Strategies (Focus: Brazil, Russia, China)
This eSummit was recorded on:
Wednesday, April 11, 2012
The files include 3 powerpoint presentations and recording of the actual eSummit
With strong economic growth, a combined population of nearly 2 billion people, and significant unmet medical needs, the market for pharmaceuticals in the BRC countries (Brazil, Russia, China) remain the biggest opportunity for commercial expansion outside of North America and Europe. However, how will the massive healthcare reforms in these regions affect your market expansion plan? Is this a time of exciting opportunity or commercial danger for foreign R&D organizations? Join the 90-minute eSummit and equip yourself with the knowledge to succeed in the BRC countries. The country-specific discussions will keep you abreast of the current market conditions and prepare for unforeseen challenges and competitions.
Ms. Martin de Bustamante’s career has focused on pharmaceutical global market access issues for specialty biologic drugs across diverse therapeutic areas. Her time has been apportioned between the emerging and developed markets, with a strong focus on Latin America (Mexico, Argentina, Colombia, Brazil), Asia (China, India, Philippines, Thailand) and Southern Europe (Spain, Italy). Through in-depth primary research conducted in the countries’ native languages Ms. Martin de Bustamante has fortified her understanding these markets’ rapidly evolving cost-containment policies.
Maria V. Avxentyeva, Doctor of Medical Sciences, is presently the Deputy Director of the Research Institute of Clinico-Economic Evaluation and Pharmacoeconomics at Russian National Research Medical University named after N.I. Pirogov and as a part-timer – Professor at the Chair of Public Health at Health Care Management Faculty of the First Moscow State Medical University named after I.M. Sechenov. She is an author of more than 200 articles concerning pharmacoeconomics, clinical guidelines and protocols development, health care quality management; co-author of the textbook “Health care management”, national guideline on clinico-economical (pharmacoeconomical) analysis and several books on economic evaluation in health care (in Russian).
Dr. Lee Grossman joint Biogen Idec in Oct 2011 is currently the Director of Emerging Markets Access. Biogen Idec is a leading global biotechnology company with more than $4 billion revenue with a rich and diverse pipeline that includes more than 20 products in Phase II clinical trials. She is responsible for creating the vision of Emerging Markets Access network, setting up the organization, strategies and details for implantation.